MDTNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends April 24
Medtronic plc
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 3, 2026
$92.77−1.98 (-2.09%)
Close on Oct 19, 2026
- Market cap
- $119.22B
- P/E (TTM)
- 22.8
- Dividend yield
- 3.06%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
86.5%
1.11B of 1.28B shares
Institutional holders
2,126
169 new, 244 sold out
Net institutional buying
15M
In Q2 2026
Insider trades, 12 months
0 buys · 16 sales
Net sold $8.92M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Vanguard Capital Management | 96,424,044 | 7.51% | 13G (passive) | Mar 31, 2026 |
| BlackRock, Inc. | 88,655,585 | 6.90% | 13G (passive) amendment | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MDT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 114,020,787 | 8.91% | $8.92B | +838,220 | 0.13% |
| Vanguard Capital Management LLC | 83,816,735 | 6.55% | $6.56B | +482,902 | 0.14% |
| State Street Corp | 63,399,315 | 4.96% | $5.01B | +1,658,301 | 0.15% |
| Vanguard Portfolio Management LLC | 34,059,967 | 2.66% | $2.66B | +609,409 | 0.12% |
| Geode Capital Management, LLC | 30,192,015 | 2.36% | $2.35B | +1,455,674 | 0.13% |
| JPMorgan Chase & Co | 27,784,471 | 2.17% | $2.25B | −23,189,070 | 0.12% |
| First Eagle Investment Management, LLC | 27,567,966 | 2.16% | $2.16B | +17,523,271 | 1.79% |
| Bank Of America Corp /De/ | 21,322,401 | 1.67% | $1.67B | −4,692,602 | 0.11% |
| Massachusetts Financial Services Co /Ma/ | 19,872,600 | 1.55% | $2.61B | −1,564,999 | 0.83% |
| Morgan Stanley | 19,444,871 | 1.52% | $1.52B | −1,272,158 | 0.08% |
| Deutsche Bank AG\ | 18,449,877 | 1.44% | $1.44B | −552,537 | 0.42% |
| Invesco Ltd. | 17,885,150 | 1.40% | $1.40B | +1,098,152 | 0.11% |
| Franklin Resources Inc | 17,550,983 | 1.37% | $1.37B | +3,375,304 | 0.30% |
| Norges Bank | 16,551,016 | 1.29% | $1.29B | New | 0.13% |
| Royal Bank of Canada | 16,026,475 | 1.25% | $1.25B | +1,846,658 | 0.19% |
| Bank of New York Mellon Corp | 14,694,253 | 1.15% | $1.15B | −807,616 | 0.19% |
| Capital Research Global Investors | 13,261,310 | 1.04% | $1.04B | −28,665,280 | 0.14% |
| Arrowstreet Capital, Limited Partnership | 12,892,710 | 1.01% | $1.01B | +8,233,285 | 0.45% |
| Northern Trust Corp | 11,626,741 | 0.91% | $909.56M | −410,080 | 0.11% |
| Ameriprise Financial Inc | 11,565,988 | 0.90% | $904.73M | −413,943 | 0.18% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 2,126 | 1.11B | 86.5% | 169 / 848 | 916 / 244 | 143M | 127M |
| Q1 2026 | 2,239 | 1.09B | 85.6% | 185 / 904 | 893 / 211 | 214M | 84M |
| Q4 2025 | 2,306 | 1.10B | 85.8% | 291 / 879 | 880 / 108 | 69M | 95M |
| Q3 2025 | 2,171 | 1.13B | 88.2% | 190 / 917 | 816 / 127 | 123M | 90M |
| Q2 2025 | 2,139 | 1.09B | 85.6% | 147 / 880 | 876 / 147 | 75M | 58M |
| Q1 2025 | 2,167 | 1.08B | 84.4% | 209 / 940 | 799 / 126 | 77M | 61M |
| Q4 2024 | 2,118 | 1.07B | 83.5% | 247 / 787 | 885 / 154 | 80M | 84M |
| Q3 2024 | 2,056 | 1.08B | 84.6% | 180 / 756 | 902 / 116 | 175M | 70M |
| Q2 2024 | 2,016 | 1.09B | 85.2% | 141 / 822 | 835 / 162 | 33M | 121M |
| Q1 2024 | 2,065 | 1.18B | 92.4% | 176 / 929 | 726 / 148 | 90M | 44M |
| Q4 2023 | 2,066 | 1.14B | 89.1% | 272 / 647 | 986 / 135 | 104M | 55M |
| Q3 2023 | 1,959 | 1.09B | 85.4% | 116 / 916 | 732 / 173 | 41M | 36M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of MDT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 40,757,422 | 3.19% | $3.19B | 0.14% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 33,271,457 | 2.60% | $2.60B | 0.16% | Jun 30, 2026 |
| Vanguard Value Index Fund | 12,221,643 | 0.96% | $956.10M | 0.38% | Jun 30, 2026 |
| Vanguard Dividend Appreciation Index Fund | 7,264,159 | 0.57% | $620.29M | 0.47% | Jul 31, 2026 |
| Vanguard Institutional Index Fund | 6,970,004 | 0.54% | $545.26M | 0.16% | Jun 30, 2026 |
| Dodge & Cox Stock Fund | 5,743,900 | 0.45% | $449.35M | 0.38% | Jun 30, 2026 |
| Vanguard Windsor Ii Fund | 5,314,118 | 0.42% | $453.77M | 0.68% | Jul 31, 2026 |
| Vanguard High Dividend Yield Index Fund | 5,164,324 | 0.40% | $440.98M | 0.44% | Jul 31, 2026 |
| WCM Focused International Growth Fund | 4,354,530 | 0.34% | $340.65M | 1.51% | Jun 30, 2026 |
| Vanguard Health Care Fund | 4,228,128 | 0.33% | $361.04M | 0.95% | Jul 31, 2026 |
| Vanguard Health Care Index Fund | 3,849,568 | 0.30% | $284.14M | 1.50% | May 31, 2026 |
| iShares Russell 1000 Value ETF | 2,864,802 | 0.22% | $224.11M | 0.28% | Jun 30, 2026 |
| Invesco S&P 500 Equal Weight ETF | 2,321,607 | 0.18% | $198.24M | 0.21% | Jul 31, 2026 |
| Invesco Value Opportunities Fund | 2,314,922 | 0.18% | $197.67M | 2.17% | Jul 31, 2026 |
| Equity Income Fund | 1,925,722 | 0.15% | $150.65M | 2.33% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Geoffrey Martha | Chairman and CEO, Director | 327,866 | 0.03% | Aug 4, 2026 |
| Harry Skip Kiil | EVP & President Cardiovascular | 42,186 | 0.00% | Sep 17, 2026 |
| Denise L. Blomquist | Chief Accounting Officer | 16,398 | 0.00% | Sep 16, 2026 |
| Michael Marinaro | EVP, Pres MedSurg and Americas | 116,336 | 0.01% | Aug 24, 2026 |
| Kweli Thompson | EVP & President, Neuroscience | 35,390 | 0.00% | Aug 4, 2026 |
| Matthew R. Walter | SVP, Chief HR Officer | 39,928 | 0.00% | Aug 4, 2026 |
| Michelle Quinn | EVP, GC and Secretary | 26,721 | 0.00% | Aug 4, 2026 |
| Thierry Pieton | EVP & Chief Financial Officer | 49,645 | 0.00% | Aug 4, 2026 |
| Brett A. Wall | EVP & Pres Neuroscience | 82,183 | 0.01% | May 28, 2026 |
| Gregory L. Smith | EVP Global Ops & Supply Chain | 51,830 | 0.00% | Nov 21, 2025 |
| Gary Louis Corona | Interim CFO | 44,255 | 0.00% | Jan 23, 2025 |
| Ivan K. Fong | EVP GENERAL COUNSEL & SECR | 54,692 | 0.00% | Dec 17, 2024 |
| Sean Salmon | EVP & President Cardiovascular | 64,722 | 0.01% | Dec 17, 2024 |
| Jennifer M. Kirk | Chief Accounting Officer | 28,011 | 0.00% | Dec 10, 2024 |
| Joon Sup Lee | Director | 1,803 | 0.00% | Apr 29, 2026 |
| Craig Arnold | Director | 42,185 | 0.00% | Apr 29, 2026 |
| William R. Jellison | Director | 6,444 | 0.00% | Apr 29, 2026 |
| Scott C. Donnelly | Director | 23,924 | 0.00% | Apr 29, 2026 |
| Randall J. Hogan | Director | 86,082 | 0.01% | Apr 29, 2026 |
| Kendall J. Powell | Director | 54,380 | 0.00% | Apr 29, 2026 |
| Lidia Fonseca | Director | 7,644 | 0.00% | Apr 29, 2026 |
| Kevin E. Lofton | Director | 10,140 | 0.00% | Apr 29, 2026 |
| Elizabeth G. Nabel | Director | 19,584 | 0.00% | Apr 29, 2026 |
| John P. Groetelaars | Director | 1,444 | 0.00% | Apr 29, 2026 |
| Gregory P. Lewis | Director | 5,754 | 0.00% | Apr 29, 2026 |
| Andrea Jo Goldsmith | Director | 10,247 | 0.00% | Apr 30, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Harry Skip Kiil EVP & President Cardiovascular | Sep 16, 2026 | Sale | −1,483 | $93.65 | $138.88K | 42,186 |
| Denise L. Blomquist Chief Accounting Officer | Sep 15, 2026 | Gift | −600 | – | – | 16,398 |
| Michael Marinaro EVP, Pres MedSurg and Americas | Aug 20, 2026 | Tax withholding | −1,084 | $92.30 | $100.05K | 116,336 |
| Denise L. Blomquist Chief Accounting Officer | Aug 3, 2026 | Award | +2,337 | – | – | 16,998 |
| Michael Marinaro EVP, Pres MedSurg and Americas | Aug 3, 2026 | Award | +10,960 | – | – | 71,273 |
| Michael Marinaro EVP, Pres MedSurg and Americas | Aug 3, 2026 | Award | +46,147 | – | – | 117,420 |
| Thierry Pieton EVP & Chief Financial Officer | Aug 3, 2026 | Award | +11,537 | – | – | 49,645 |
| Michelle Quinn EVP, GC and Secretary | Aug 3, 2026 | Award | +6,346 | – | – | 26,721 |
| Harry Skip Kiil EVP & President Cardiovascular | Aug 3, 2026 | Award | +9,230 | – | – | 43,669 |
| Matthew R. Walter SVP, Chief HR Officer | Aug 3, 2026 | Award | +5,769 | – | – | 39,928 |
| Geoffrey Martha Chairman and CEO, Director | Aug 3, 2026 | Award | +41,533 | – | – | 327,866 |
| Kweli Thompson EVP & President, Neuroscience | Aug 3, 2026 | Award | +6,923 | – | – | 35,390 |
| Denise L. Blomquist Chief Accounting Officer | Jul 31, 2026 | Tax withholding | −212 | $85.39 | $18.10K | 14,661 |
| Michael Marinaro EVP, Pres MedSurg and Americas | Jul 31, 2026 | Tax withholding | −3,356 | $85.39 | $286.57K | 60,313 |
| Harry Skip Kiil EVP & President Cardiovascular | Jul 31, 2026 | Tax withholding | −3,074 | $85.39 | $262.49K | 34,439 |
| Matthew R. Walter SVP, Chief HR Officer | Jul 31, 2026 | Tax withholding | −1,675 | $85.39 | $143.03K | 34,159 |
| Geoffrey Martha Chairman and CEO, Director | Jul 31, 2026 | Tax withholding | −15,810 | $85.39 | $1.35M | 286,333 |
| Kweli Thompson EVP & President, Neuroscience | Jul 31, 2026 | Tax withholding | −1,739 | $85.39 | $148.49K | 28,467 |
| Michelle Quinn EVP, GC and Secretary | Jul 28, 2026 | Tax withholding | −2,069 | $86.88 | $179.75K | 20,375 |
| Matthew R. Walter SVP, Chief HR Officer | Jul 8, 2026 | Sale(10b5-1 plan) | −3,102 | $83.15 | $257.93K | 35,694 |
| Harry Skip Kiil EVP & President Cardiovascular | Jun 8, 2026 | Sale | −3,961 | $80.44 | $318.62K | 37,455 |
| Harry Skip Kiil EVP & President Cardiovascular | Jun 8, 2026 | Sale | −228 | $80.45 | $18.34K | 37,227 |
| Denise L. Blomquist Chief Accounting Officer | Jun 5, 2026 | Tax withholding | −237 | $83.32 | $19.75K | 14,737 |
| Michael Marinaro EVP, Pres MedSurg and Americas | Jun 4, 2026 | Tax withholding | −7,471 | $83.32 | $622.48K | 63,122 |
| Geoffrey Martha Chairman and CEO, Director | Jun 4, 2026 | Tax withholding | −41,936 | $83.32 | $3.49M | 301,163 |
| Harry Skip Kiil EVP & President Cardiovascular | Jun 4, 2026 | Tax withholding | −6,817 | $83.32 | $567.99K | 41,416 |
| Matthew R. Walter SVP, Chief HR Officer | Jun 4, 2026 | Tax withholding | −2,840 | $83.32 | $236.63K | 38,689 |
| Denise L. Blomquist Chief Accounting Officer | May 26, 2026 | Option exercise | +1,712 | – | – | 14,974 |
| Michael Marinaro EVP, Pres MedSurg and Americas | May 26, 2026 | Option exercise | +18,994 | – | – | 70,593 |
| Geoffrey Martha Chairman and CEO, Director | May 26, 2026 | Option exercise | +94,963 | – | – | 343,099 |
| Brett A. Wall EVP & Pres Neuroscience | May 26, 2026 | Option exercise | +26,907 | – | – | 82,183 |
| Harry Skip Kiil EVP & President Cardiovascular | May 26, 2026 | Option exercise | +15,195 | – | – | 48,233 |
| Matthew R. Walter SVP, Chief HR Officer | May 26, 2026 | Option exercise | +9,149 | – | – | 41,529 |
| Matthew R. Walter SVP, Chief HR Officer | May 1, 2026 | Tax withholding | −35 | $80.00 | $2.80K | 32,380 |
| Lidia Fonseca Director | Apr 28, 2026 | Tax withholding | −207 | $81.90 | $16.95K | 7,644 |
| Gregory P. Lewis Director | Apr 28, 2026 | Tax withholding | −207 | $81.90 | $16.95K | 5,754 |
| Kendall J. Powell Director | Apr 28, 2026 | Tax withholding | −207 | $81.90 | $16.95K | 51,380 |
| Kevin E. Lofton Director | Apr 28, 2026 | Tax withholding | −207 | $81.90 | $16.95K | 10,140 |
| Elizabeth G. Nabel Director | Apr 28, 2026 | Tax withholding | −207 | $81.90 | $16.95K | 19,584 |
| Randall J. Hogan Director | Apr 28, 2026 | Tax withholding | −207 | $81.90 | $16.95K | 48,998 |
| Denise L. Blomquist Chief Accounting Officer | Apr 28, 2026 | Tax withholding | −318 | $81.90 | $26.04K | 13,262 |
| Craig Arnold Director | Apr 28, 2026 | Tax withholding | −207 | $81.90 | $16.95K | 42,185 |
| Scott C. Donnelly Director | Apr 28, 2026 | Tax withholding | −207 | $81.90 | $16.95K | 23,679 |
| Lidia Fonseca Director | Apr 27, 2026 | Award | +2,111 | – | – | 7,851 |
| William R. Jellison Director | Apr 27, 2026 | Award | +1,444 | – | – | 6,444 |
| Gregory P. Lewis Director | Apr 27, 2026 | Award | +2,111 | – | – | 5,961 |
| Kendall J. Powell Director | Apr 27, 2026 | Award | +2,111 | – | – | 51,587 |
| Kevin E. Lofton Director | Apr 27, 2026 | Award | +2,111 | – | – | 10,347 |
| Elizabeth G. Nabel Director | Apr 27, 2026 | Award | +2,111 | – | – | 19,791 |
| Randall J. Hogan Director | Apr 27, 2026 | Award | +2,111 | – | – | 49,205 |
| Denise L. Blomquist Chief Accounting Officer | Apr 27, 2026 | Award | +1,508 | – | – | 13,580 |
| Craig Arnold Director | Apr 27, 2026 | Award | +2,111 | – | – | 42,392 |
| Joon Sup Lee Director | Apr 27, 2026 | Award | +1,803 | – | – | 1,803 |
| Scott C. Donnelly Director | Apr 27, 2026 | Award | +2,111 | – | – | 23,886 |
| John P. Groetelaars Director | Apr 27, 2026 | Award | +1,444 | – | – | 1,444 |
| Thierry Pieton EVP & Chief Financial Officer | Mar 3, 2026 | Tax withholding | −2,976 | $96.71 | $287.81K | 37,574 |
| Denise L. Blomquist Chief Accounting Officer | Feb 20, 2026 | Gift | −340 | – | – | 11,966 |
| Harry Skip Kiil EVP & President Cardiovascular | Feb 19, 2026 | Sale | −668 | $97.83 | $65.35K | 33,153 |
| Harry Skip Kiil EVP & President Cardiovascular | Feb 19, 2026 | Option exercise | +30,568 | $93.08 | $2.85M | 64,984 |
| Harry Skip Kiil EVP & President Cardiovascular | Feb 19, 2026 | Option exercise | +19,923 | $87.76 | $1.75M | 84,907 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Geoffrey Martha Officer, Director | Oct 15, 2026 | 50,000 | $4.75M | Oct 15, 2026 | Restricted Stock Vesting |
| Michael Marinaro Officer | Oct 15, 2026 | 10,420 | $1.00M | Oct 15, 2026 | ESPP Purchase |
| Harry Skip Kiil Officer | Sep 16, 2026 | 1,483 | $138.89K | Sep 16, 2026 | Restricted Stock Vesting |
| Matthew R. Walter Officer | Jul 8, 2026 | 3,102 | $257.93K | Jul 8, 2026 | ESPP Purchase |
| Harry Skip Kiil Officer | Jun 8, 2026 | 4,189 | $336.97K | Jun 8, 2026 | Restricted Stock Vesting |
| Harry Skip Kiil Officer | Feb 19, 2026 | 52,524 | $5.13M | Feb 19, 2026 | Restricted Stock Vesting |
| Gregory L. Smith Officer | Nov 19, 2025 | 30,000 | $3.06M | Nov 19, 2025 | ESPP Purchase |
| Harry Skip Kiil Officer | Sep 3, 2025 | 8,605 | $788.05K | Sep 3, 2025 | Restricted Stock Vesting |
| Sean Salmon Officer | Jun 6, 2025 | 18,378 | $1.60M | Jun 6, 2025 | Option Granted 08/03/2015 |
| Brett A. Wall Officer | Jan 24, 2025 | 12,437 | $1.12M | Jan 24, 2025 | Options Granted 08/03/2015 |
| Brett A. Wall Officer | Jan 8, 2025 | 9,850 | $792.04K | Jan 8, 2025 | Stock Option Exercise |
| Karen L. Parkhill Former Director | Oct 31, 2024 | 30,000 | $2.69M | Oct 31, 2024 | Option Granted- 07/30/2018 |
| Karen L. Parkhill Former Director | Oct 30, 2024 | 15,000 | $1.36M | Oct 30, 2024 | Option Granted- 07/30/2018 |
| Karen L. Parkhill Former BOD | Oct 29, 2024 | 15,000 | $1.37M | Oct 29, 2024 | Option Granted - 07/30/2018 |
| Karen L. Parkhill Former Director | Oct 24, 2024 | 22,712 | $2.10M | Oct 24, 2024 | Options Granted 08/01/2016 |